NASDAQ:ADVM - Adverum Biotechnologies Stock Price, Forecast & News

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Adverum Biotechnologies Inc (NASDAQ:ADVM) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $0.25 million during the quarter, compared to analyst estimates of $0.48 million. View Adverum Biotechnologies' Earnings History.

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Adverum Biotechnologies.

6 analysts have issued 12-month price targets for Adverum Biotechnologies' shares. Their forecasts range from $8.00 to $12.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $9.50 in the next year. This suggests that the stock has a possible downside of 9.9%. View Analyst Price Targets for Adverum Biotechnologies.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adverum Biotechnologies.

Press coverage about ADVM stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Adverum Biotechnologies earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Adverum Biotechnologies.

Adverum Biotechnologies saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 8,190,000 shares, a drop of 15.9% from the September 15th total of 9,740,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is currently 4.1 days. Currently, 15.8% of the company's shares are short sold. View Adverum Biotechnologies' Current Options Chain.

Some companies that are related to Adverum Biotechnologies include Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Alector (ALEC), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Precision BioSciences (DTIL) and Aerie Pharmaceuticals (AERI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Immunomedics (IMMU), Nextera Energy Partners (NEP), Chipotle Mexican Grill (CMG) and Buckeye Partners (BPL).

Adverum Biotechnologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (7.50%), Orbimed Advisors LLC (6.21%), Squarepoint Ops LLC (0.31%), California Public Employees Retirement System (0.21%), Voloridge Investment Management LLC (0.18%) and California State Teachers Retirement System (0.13%). View Institutional Ownership Trends for Adverum Biotechnologies.

ADVM stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Orbimed Advisors LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC, California Public Employees Retirement System, Tibra Equities Europe Ltd, SG Americas Securities LLC and Virtu Financial LLC. View Insider Buying and Selling for Adverum Biotechnologies.

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADVM stock can currently be purchased for approximately $10.55.

Adverum Biotechnologies has a market capitalization of $681.08 million and generates $1.61 million in revenue each year. The biotechnology company earns $-72,630,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.View Additional Information About Adverum Biotechnologies.

The official website for Adverum Biotechnologies is http://www.adverum.com/.

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]